Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffrey Matous (Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, open-label, multicentre phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma.